Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst

With Pfizer (PFE -2.09%) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last week, Guggenheim analyst Vamil Divan said he believes Pfizer is worth $36 per share. That would represent a gain of about 30% from Friday's closing price.Pfizer's cash generated from operations soared during the COVID-19 pandemic, and its share price soared along with it. But Pfizer stock has dropped by more than ...